Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: BridgeBio To Launch New Subsidiary Around Rare Disease Candidate Obtained From Alexion

Executive Summary

Sanofi completes the transition of its infectious disease unit to Evotec. Perhaps not yet done with virology, Gilead licenses technology for HIV/hep B vaccines from Hookipa.

Advertisement

Related Content

Shionogi Deal Opens Asia To Sage’s Fast-Acting Antidepressant
Aim High And Keep Pushing: China Biotech Dealmakers Borrow Page From Trump
Vical Faced With Failure of Another Vaccine Trial
Takeda Secures TiGenix But Investor Shire Concerns Bubble Up
Genentech Mines The Microbiome Again With IBD Deal
Indo-Korean Pharma Linkages: A New Emerging Asian Front?
Oxford BioMedica CEO To Hire More People, Expects More Deals Following Gene Therapy Pact With Axovant
Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal
Pipeline Watch: Phase III Starts For BL-8040, Trigriluzole, MIN-101
The Next Roivant Or Fortress? BridgeBio Raises $135m To Spin Out New Companies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel